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Research Letter
proportion of the cardiac cycle (EMATc) >15% was
signiﬁcantly associated with LV dysfunction.2 The
S3 is a speciﬁc marker of worsening HF in the
presence of dyspnea and an independent predictor

Audicor Remote Patient
Monitoring

of adverse clinical outcomes, including the progression of HF. 1
Wang et al evaluated whether CABs could identify

FDA Breakthrough Device and Technology

HF patients at high risk for mortality in an HF popu-

for Heart Failure Management

lation (n ¼ 474) followed for a mean of 484 days.3
There were 169 deaths (36%) with 126 (27%) due to

The impact of heart failure (HF) on patients, physi-

cardiac causes. In a multivariate Cox regression

cians, and hospital systems remains despite recent

analysis controlling for basic demographics, bio-

successes in pharmacologic and device-based treat-

markers, and medications, S3 strength remained an

ments. Chronic HF represents one of the nation’s top

independent

health issues, leading to reduced patient quality of

Kaplan-Meier analysis showed that subjects having

life, increased risks of hospitalization, increased

abnormal CABs experienced signiﬁcantly lower sur-

health care utilization, and high incidence of patient

vival (52.2% vs 69.2%; P < 0.001) compared with

morbidity and mortality. Titration of guideline-

subjects with CABs not exceeding the abnormal

directed medical therapy and prevention of HF hos-

thresholds. The authors concluded that CABs can be a

pitalizations have been identiﬁed as key targets in the

cost-effective and time-efﬁcient tool to identify HF

management of HF. Remote monitoring provides the

patients who might beneﬁt from close monitoring and

opportunity to address both issues and has gained

intervention and may improve assessment and deci-

signiﬁcant

sion making in HF management.

momentum

during

the

COVID-19

predictor

for

all-cause

mortality.

pandemic. Device-based solutions to manage HF

Chao et al investigated EMAT for prediction of HF

remotely, such as CardioMEMS and Boston Scientiﬁc

readmission or cardiac mortality in patients hospi-

HeartLogic, have demonstrated promise for the pre-

talized for acute HF (n ¼ 45) and followed for 242 

vention of HF hospitalizations but are invasive and

156 days. 4 CABs were initially assessed within 24

expensive. A noninvasive system for remote HF

hours of admission, before discharge, and 2 weeks

monitoring for easy at-home use, Audicor RPM has

after discharge. Adverse events, death or read-

recently

mission, occurred in 44% of patients. Using univari-

received

a

FDA

Breakthrough

Device

designation.

ate Cox regression analysis, postdischarge EMATc

HF management with the Audicor RPM is based

predicted postdischarge adverse events (hazard ratio

on cardiac acoustic biomarkers (CABs) that are

[HR]: 2.5; 95% CI: 1.58-3.97). After adjustment for

automatically

simulta-

covariates these predictions remained statistically

neously recorded electrocardiographic and heart

signiﬁcant. Kaplan-Meier survival analysis showed a

generated

from

tens

of

sound data by means of machine learning algo-

statistically signiﬁcantly reduced event-free survival

rithms developed on large independently validated

for patients with prolonged postdischarge EMATc

clinical databases. 1 The CABs most relevant for HF

(Figure 1D).

monitoring are electromechanical activation time

A randomized control trial recently tested Audicor

(EMAT) (ie, QRS onset to the ﬁrst heart sound in-

CAB-guided HF management vs symptom-guided

terval)

strength

management. The evaluated CABs were S3 strength

(Figure 1A). EMAT has been shown to be prolonged

and

third

heart

sound

(S3)

and EMATc.5 Patients hospitalized for HF were ran-

in patients with impaired left ventricular (LV) sys-

domized before discharge into the CAB-guided group

tolic function and correlates with LV max dP/dt.1

(n ¼ 114) or the symptom-guided group (n ¼ 111). After

Moyers et al found that EMAT expressed as a

a mean follow-up of 238  141 days, a reduction in the

Editor’s Note: To view the authors’ full presentation at TCTMD Shark Tank, please visit https://www.jacc.org/journal/basictranslational/tht-2022-shark-tank.
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F I G U R E 1 Audicor Technology, Remote Patient Monitoring (RPM), and Key Clinical Evidence

(Top) (A) Audicor CABs; (B) Audicor RPM recording device; (C) patient taking a recording. (Bottom) Kaplan-Meier curves from (D) Chao et al4 and (E) Sung et al.5
CAB ¼ cardiac acoustic biomarkers; ECG ¼ electrocardiography; EMAT ¼ electromechanical activation time; EMATc ¼ proportion of electromechanical activation time
relative to cardiac cycle; S3 ¼ third heart sound.

primary end points was seen in the CAB-guided group

from a single position on the chest (V 4). The device

vs the symptom-guided group (43 vs 61 events; P <

connects to the internet for Audicor cloud analysis,

0.001). The time to ﬁrst event favored the CAB-

resulting in CAB trends available for clinician re-

guided group (n ¼ 225; HR: 0.61; 95% CI: 0.42-0.91;

view with automated alerts for risk of HF decom-

log-rank P ¼ 0.013) over the control group and a

pensation based on ﬁxed measurement thresholds,

similar beneﬁt was seen in the subgroup of patients

which can be customized per patient. This new

(Figure 1E) with a predischarge EMATc >15%, (n ¼ 85;

system allows the previous CAB-guided HF man-

HR: 0.32; 95% CI: 0.16-0.65; log-rank P < 0.001).

agement methods to be applied in a remote moni-

The above studies were performed with the use

toring model with minimal physician involvement.

of a commercially available Audicor device that

Early

adhered to the patient with standard electrodes.

intervention and modiﬁcation of medications, thus

The novel Audicor RPM is a hand-held device

preventing hospital readmission.

intended

for

at-home

use

in

HF

identiﬁcation

of

HF

deterioration

allows

management

A prospective randomized trial of the Audicor RPM

(Figures 1B and 1C) that uses the same commercially

system for remote (at-home) monitoring to evaluate

available algorithms and equivalent signal acquisi-

the safety and effectiveness of CAB-guided HF man-

tion techniques as previous Audicor devices. Car-

agement vs symptom-guided management on pa-

diac acoustic and electrical signals are acquired

tients previously hospitalized for HF is under design
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development in collaboration with the FDA through
the

Breakthrough

Device

program.

Eligible

in-

stitutions, predominantly in the U.S., will begin

The authors attest they are in compliance with human studies committees and
animal welfare regulations of the authors’ institutions and Food and Drug
Administration guidelines, including patient consent where appropriate. For
more information, visit the Author Center.

enrolling patients in 2022.
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